Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Meta and Apple team up to make Muse AI models run better on Macs

October 15, 2026

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Artificial Intelligence in Pharmaceutical Market Research and Global Forecast Report 2026-2032
Press Release

Artificial Intelligence in Pharmaceutical Market Research and Global Forecast Report 2026-2032

By News RoomApril 9, 20264 Mins Read
Artificial Intelligence in Pharmaceutical Market Research and Global Forecast Report 2026-2032
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 09, 2026 (GLOBE NEWSWIRE) — The “Artificial Intelligence in Pharmaceutical Market – Global Forecast 2026-2032” report has been added to ResearchAndMarkets.com’s offering.

The artificial intelligence in pharmaceutical market expanded from USD 20.08 billion in 2025 to USD 25.54 billion in 2026. Projections indicate continued rapid growth at a compound annual growth rate (CAGR) of 27.68%, with the market forecast to reach USD 111.13 billion by 2032.

The artificial intelligence in pharmaceutical market is transforming industry operations as decision-makers embrace advanced analytics and machine learning to drive innovation, efficiency, and compliance in a growingly complex and competitive landscape.

This expansion reflects sustained digital transformation across discovery, clinical development, and commercial operations, supported by ongoing investment from pharmaceutical and biotechnology companies seeking to optimize research and development pipelines, navigate regulatory landscapes, and streamline operational performance.

Key Takeaways for Leaders

  • Strategic adoption of artificial intelligence is reshaping pharmaceutical research and development, offering scalable options to address intricate data landscapes and resource constraints.
  • Integrating advanced machine learning into clinical workflows requires multidisciplinary talent, robust governance, and trusted partnerships to achieve compliance and innovation simultaneously.
  • The industry trend moves from experimental applications to the operationalization of AI, with significant investments in model governance, data lineage, and reproducibility to align with evolving regulatory expectations.
  • Flexible operational models, including cloud-native solutions and managed services, improve resilience and adaptability as procurement and technology strategies mature within enterprises.
  • Differences in regional regulatory scrutiny, data infrastructure, and privacy standards require tailored deployment and validation efforts, ensuring that adoption aligns with local compliance and operational contexts.
  • Organizations realizing sustained competitive advantage align AI technology choices, deployment approaches, and external support with their specific therapeutic concentrations and internal structures.

Market Snapshot, Scope & Segmentation

  • Component: Spans managed and professional services for deployment, integration, and lifecycle management, as well as software solutions supporting clinical trial management platforms, diagnostic applications, drug discovery suites, regulatory compliance tools, and supply chain management systems.
  • Technology: Incorporates computer vision for imaging and object detection, deep learning frameworks (including convolutional and recurrent neural networks and transformers), machine learning approaches (such as supervised, unsupervised, and reinforcement learning), natural language processing for text and speech analysis, and robotic process automation to streamline routine tasks.
  • Therapeutic Focus: Includes cardiovascular, immunology, infectious diseases, metabolic diseases, neurology, oncology, and respiratory applications, each influencing the selection of AI methodologies and validation strategies due to unique clinical and regulatory demands.
  • Application: Covers clinical trials management, patient recruitment, predictive analytics, drug discovery (from design and validation to lead optimization and target selection), personalized healthcare (including biomarker discovery and genomic profiling), and supply chain management such as demand forecasting and logistics optimization.
  • Deployment: Addresses cloud-based, on-premises, and hybrid models, offering solutions tailored to diverse scalability, security, and compliance needs in varying operational environments.
  • End User: Serves pharmaceutical and biotechnology firms, contract research organizations, and academic and research institutions, each with distinct risk profiles and preferences for internal or collaborative innovation.
  • Region: Focuses on the Americas, Europe, Middle East & Africa, and Asia-Pacific, with variations in regulatory frameworks, data privacy requirements, and availability of skilled talent shaping regional adoption and implementation strategies.

Why This Report Matters

  • Equips senior decision-makers with guidance for responding to rapid regulatory, technological, and operational changes in pharmaceutical AI adoption.
  • Supports informed investment and procurement by clarifying best practices and highlighting evolving strategies within the marketplace.
  • Enables organizations to mitigate risk as they scale AI programs, with insight tailored to therapeutic areas, regional differences, and unique organizational needs.

Conclusion

Artificial intelligence is now a fundamental component of pharmaceutical strategy, enabling businesses to enhance agility, strengthen validation, and improve operational efficiency. Sustainable advantage is achieved when technology, governance, and deployment are closely aligned with market realities.

Key Attributes:

Report Attribute Details
No. of Pages 195
Forecast Period 2026 – 2032
Estimated Market Value (USD) in 2026 $25.54 Billion
Forecasted Market Value (USD) by 2032 $111.13 Billion
Compound Annual Growth Rate 27.6%
Regions Covered Global

Companies Featured

  • AiCure, LLC
  • Aspen Technology Inc.
  • Atomwise Inc.
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica by Recursion Pharmaceuticals, Inc.
  • Deargen Inc.
  • Deep Genomics Incorporated
  • Deloitte Touche Tohmatsu Limited
  • Euretos Services BV
  • Exscientia PLC
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs Limited
  • Microsoft Corporation
  • Novo Nordisk A/S
  • NVIDIA Corporation
  • Oracle Corporation
  • SANOFI WINTHROP INDUSTRIE
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.

For more information about this report visit https://www.researchandmarkets.com/r/zg5cvq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Artificial Intelligence in Pharmaceutical Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

vineyard vines Returns as Official Style of the Head Of The Charles® Regatta

Bigger & Better Than Ever: Laxmi & Chef Kunal Kapur Return With ‘Diwali Delights’ Season 2

2026 Chery International User Summit to Kick Off: LUXEED Set for Global Brand Launch

Going Asset Management Wins Capital’s Excellence Fund Award, Harnessing Technology to Enhance the Long-Term Value of Assets

Alation Honors 2026 AI Radicals Award Winners at revAlation

Supported Employment: Helping Individuals Build Meaningful Careers

“The Carbon Pursuit of Happiness” Premieres October 10: A New Chapter for In-Depth Dialogue on Health and Humanity

Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to 11 Million and Reaffirms 460 Million Fiscal 2027 Outlook

Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading

Editors Picks

Calgary Stampeders need help to reach CFL playoffs

October 15, 2026

Flintstones vitamins, Aleve and Claritin tablets hit in new recall

October 15, 2026

Sony made a $5,900 gold-plated Walkman MP3 player

October 15, 2026

Fisheries sector fund gets $300 million extension from Ottawa, Atlantic provinces

October 15, 2026

Latest News

Friends don’t let friends feed their data to AI agents

October 15, 2026

As bond yields rise, how to pick between a variable or fixed rate mortgage?

October 15, 2026

Carney says he expects nations, including U.S., to stay out of Alberta vote

October 15, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version